Skip to main content
Erschienen in: BMC Endocrine Disorders 1/2021

Open Access 01.12.2021 | Case report

Apoplexy of Crooke cell tumour leading to the diagnosis of severe Cushing disease; a case report

verfasst von: Nipun Lakshitha de Silva, Noel Somasundaram, Roshana Constantine, Himashi Kularatna

Erschienen in: BMC Endocrine Disorders | Ausgabe 1/2021

Abstract

Background

Patients with Crooke cell tumours present with features of Cushing syndrome or mass effect. There are few reports of patients with Crooke cell tumours presenting due to apoplexy. All of them had silent tumours. Patients with Cushing syndrome caused by Crooke cell tumours have not been reported to present with apoplexy.

Case presentation

A 35-year-old female presented with sudden onset headache and visual loss for 1 week. She had secondary amenorrhoea for 10 years. There were features of Cushing syndrome including central obesity, multiple monomorphic acne, dorso-cervical and supraclavicular fat pads, hypertension, proximal weakness, pigmentation and refractory hypokalaemia. She was found to have markedly elevated serum cortisol, central hypothyroidism and hypogonadotropic hypogonadism. There was a mass in the sellar region (4.7 cm × 1.9 cm × 5.3 cm) suggestive of a pituitary tumour extending to the suprasellar region. Imaging showed evidence of bleeding and compression of the optic chiasm. She underwent urgent trans-sphenoidal excision of the tumour. Histology was compatible with a pituitary neuroendocrine tumour. There was margination of ACTH reactivity to the cell periphery and ring like positivity in most of the cells in the cytokeratin stain. Features were in favour of a Crooke cell tumour. After surgery she improved gradually and became eucortisolaemic.

Conclusions

This is a unique presentation of an apoplexy of Crooke cell tumour causing Cushing syndrome. Delayed health seeking behaviour of this patient despite severe Cushing disease could have led to this presentation which has not been reported before.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ACTH
adrenocorticotropic hormone
MRI
Magnetic resonance imaging

Background

Crooke cell tumour is a rare type of pituitary neuroendocrine tumour containing Crooke’s hyaline material in the cytoplasm of more than 50% of the tumour cells [1, 2]. These tumour cells stain positively for adrenocorticotropic hormone (ACTH). They have variable degrees of clinical expression of Cushing syndrome. Silent pituitary tumours were reported in 25–35% of the patients [1, 2]. About 80% of these tumours are macroadenomas. Cavernous sinus invasion and suprasellar extension are seen in more than 70% [1, 2]. These tumours tend to be aggressive even following surgical removal with more than 60% recurrence rate [1].
Pituitary apoplexy is haemorrhagic infarction of a pituitary tumour presenting with headache, visual disturbances and sometimes haemodynamic instability [3]. This complication is mostly seen in patients with non-functioning pituitary neuroendocrine tumours and is rare in Cushing disease [4, 5]. Pituitary apoplexy in Cushing disease is limited to several case reports. Cushing syndrome in most of them was diagnosed before the onset of apoplexy [6]. There are few case reports of apoplexy in Crooke cell tumours, all of them being silent. This is in contrast to the fact that most of the Crooke cell tumours are hormonally active [710]. We report a young female with previously undiagnosed Cushing disease caused by Crooke cell tumour presenting due to pituitary apoplexy.

Case presentation

A 35-year-old Sri Lankan female presented with sudden onset painless visual loss leading to complete blindness in the left eye and partial visual loss in the right eye accompanied by sudden onset bilateral frontal headache for 1 week.
On questioning, multiple features of Cushing syndrome were revealed including recent onset weight gain, darkening of skin, widespread acne and difficulty in getting up from the squatting position over several months. She had not sought any medical advice. There was secondary amenorrhoea for 10 years. During the few medical consultations she had for mild acute illnesses, the possibility of Cushing syndrome had not been considered.
Personal medical and family history was unremarkable. There was no history of exposure to any psychoactive substances or glucocorticoids. She was single; and a preschool teacher.
She was alert and oriented, having central obesity with a weight of 67.6 kg and height of 148 cm. Her Body mass index was 30.86 kg/m2. She had pigmentation, multiple monomorphic acne over the face and upper chest (Fig. 1a and b). There were dorso-cervical and supraclavicular fat pads and thin skin over the extremities.
Complete blindness of the left eye and ability to count fingers from the right eye with temporal visual loss were noted (Fig. 2a). The rest of the cranial nerve functions were normal including normal eye movements. She was unable to stand from the squatting position without support. Blood pressure was 150/90 mmHg. The rest of the examination was normal.
Investigations on presentation are summarized in Table 1. Serum potassium remained less than 3 mmol/l persistently despite replacement. There was metabolic alkalosis. Serum cortisol throughout the day was over 1000 nmol/L. Free T4 was 1.04 ng/dL (0.89–1.76) with TSH 0.116 mIU/L (0.5–4.7) whereas LH and FSH levels were low (< 0.007 IU/L and < 0.03 IU/L respectively).
Table 1
Summary of Laboratory investigations on presentation
Investigation
Result
Reference range
Haemoglobin (g/dL)
11.6
11–16
White Cell Count (× 109/L)
7.34
4–11
Platelet Count (×109/L)
161
150–450
C- Reactive Protein (mg/L)
< 2
< 6
Serum Creatinine (mg/dL)
0.59
0.5–1.1
Sodium (mmol/L)
141
135–145
Potassium (mmol/L)
2.2
3.5–5.1
24 h urinary potassium excretion (mmol/24 h)
34.56
25–125
Urinalysis
normal
 
Aspartate transaminase (U/L)
41
< 40
Alanine transaminase (U/L)
52
< 40
Albumin (g/dL)
3.8
3.5–4.5
Globulin (g/dL)
2.3
2.2–3.5
Bilirubin (mg/dL)
1
0.5–1.1
Fasting blood glucose (mg/dL)
135
< 100
HbA1C (%)
5.8
4–5.7
Arterial blood pH
7.57
7.35–7.45
Arterial Bicarbonate (mmol/L)
35
24–28
Thyroid stimulating hormone (mIU/l)
0.116
0.5–4.7
Free T4 (ng/dl)
1.04
0.89–1.76
9 am cortisol (nmol/l)
1451
118–618
Prolactin (mIU/l)
237
102–496
Follicle stimulating hormone (IU/L)
< 0.3
 
Luteinising hormone (IU/L)
< 0.07
 
Insulin like growth factor-1 (ng/ml)
87
81–278
Dual-energy X-ray absorptiometry
Bone mineral Density (g/cm2)
Lumbar spine: 0.814
Right hip: 1.017
Left hip: 0.979
Z-score
Lumbar spine: −2.0
Right hip: 0.6
Left hip: 0.4
Cortisol day curve prior to surgery is shown in Table 2.
Table 2
Cortisol day curve before and 2 weeks after surgery
Time
Cortisol value (Pre-op) nmol/l
Cortisol value (Post-op) nmol/l
9 am
1451
261
11 am
1094
309
1 pm
1477
300
3 pm
1394
210
5 pm
1358
187
MRI pituitary showed a heterogeneously enhancing mass in the sellar region (4.7 cm × 1.9 cm × 5.3 cm) extending to the suprasellar region with high T1 fluid level. The pituitary gland was not seen separately (Fig. 3a and b). Features were in favour of a pituitary tumour with bleeding into it. She underwent trans-sphenoidal excision of the tumour 8 days after presentation. Histology was compatible with a pituitary neuroendocrine tumour. On H&E staining, there were cells with basophilic, granular cytoplasm and round nuclei and cells with homogeneous pink cytoplasm. The Ki 67 index was < 1% and p53 staining was 3%. Immunohistochemical staining with ACTH revealed margination of ACTH reactivity to the cell periphery and perinuclear region. The cytokeratin stain (AE1/AE3) showed ring like positivity in most of the cells. These findings were suggestive of a Crooke cell tumour (Fig. 4).
She was started on hydrocortisone and levothyroxine following surgery. Hypokalaemia improved gradually. Her 9 am cortisol after surgery was 261 nmol/L without replacement. Cortisol day curve 2 weeks after surgery without replacement is shown in Table 2.
She improved gradually with regards to pigmentation, acne, facial appearance and proximal weakness (Fig. 1c and d). Blood pressure normalized to 130/80 mmHg. Fasting blood glucose was 98 mg/dl. She regained vision in the left eye with ability to count fingers (Fig. 2b). Three months after surgery, the MRI pituitary showed no evidence of a residual tumour (Fig. 3c and d). Cortisol value in overnight dexamethasone suppression test was < 15 nmol/L. Twenty four hour urinary cortisol excretion was 71.93 μg (55.8–286) and morning cortisol was 181 nmol/L.
Levothyroxine was continued. She was advised to keep stress doses of hydrocortisone. Cyclical oestrogen and progesterone replacement therapy was initiated. The 1 year follow up MRI did not show evidence of tumour recurrence. Twenty four hour urinary free cortisol was 75.07 nmol/24 h (55.5–286). The patient was satisfied with her clinical outcome. The timeline of events are summarised in Table 3.
Table 3
Timeline of events with diagnostic tests and interventions
Month/year
Events
Diagnostic tests
Interventions
2009
Secondary amenorrhoea
None
None
From beginning of 2019
weight gain, darkening of skin, multiple acne and difficulty in getting up from squatting position
None
None
August/2019
Sudden onset headache and blindness
Visual assessment: complete blindness of left eye and finger counting from right eye with temporal visual loss
MRI-pituitary: giant pituitary tumour with bleeding
Biochemistry: hypokalaemia, elevated cortisol, central hypothyroidism, low FSH, LH
Trans-sphenoidal excision of the pituitary tumour
Histology: Crooke cell tumour
Started levothyroxine and hydrocortisone replacement
November/2019
Follow up
MRI-pituitary: No residual tumour
Visual field: bitemporal hemianopia (improved)
Twenty four hour urinary cortisol: normal
9 am cortisol: 181 nmol/L
Started cyclical oestrogen and progesterone, levothyroxine continued
September/2020
Follow up
MRI-pituitary: No residual tumour
Twenty four hour urinary cortisol: normal
Continued same treatment

Discussion and conclusions

Apoplexy in patients with Cushing disease is rare and limited to case reports. Patients with Crooke cell tumours present with Cushing disease or due to mass effects when they are hormonally silent. We did not come across any report of a patient with Crooke cell tumour causing Cushing syndrome presenting due to apoplexy.
There are few case reports of apoplexy in Crooke cell tumours. All of them are in the background of silent tumours. In a 49-year-old female with pituitary apoplexy, subsequent histology was suggestive of Crooke cell tumour. Patient did not have clinical or biochemical evidence of Cushing disease [7]. A 64-year-old male developed apoplexy and did not have any clinical features of Cushing disease. He had a history of a pituitary tumour resection more than a decade before with unknown histology. The recent histology suggested Crooke cell tumour. Preoperative ACTH and cortisol were elevated, but in the setting of acute stress [8].
In a case report of a 45-year-old male, authors describe the interesting finding of apoplexy and two intracranial pseudoaneurysms in a patient with Crooke cell tumour. Clinical and biochemical features were in favour of a silent pituitary adenoma [9]. In another report of a 55-year-old female with apoplexy, endocrine evaluation has suggested a non-functioning pituitary adenoma. It was subsequently diagnosed as a Crooke cell tumour based on histology [10].
Our patient’s clinical picture is quite different from the patients described above. She had obvious features of Cushing syndrome which resolved after surgical resection of the tumour. These included refractory hypokalaemia and multiple discriminatory features such as dorsocervial and supraclavicular fat pads, proximal weakness, multiple monomorphic acne, round face and pigmentation. Therefore this is likely to be the first reported case of apoplexy in a patient with active Cushing disease due to a Crooke cell tumour. This unique presentation could have been partly contributed to by the delayed health seeking behaviour.
There were few limitations we had to face in our setting. We could not arrange ACTH assay or overnight dexamethasone suppression test prior to surgery. She underwent surgery soon after referral to the neurosurgical and endocrine teams as a sight saving measure. We used AE1/AE3 stain as the cytokeratin stain. More specific stain recommended to identify Crooke hyaline is Cam 5.2 [1]. Since this was not available in our setup, we had to depend on the available cytokeratin stain. However in the given context of aggressive pituitary neuroendocrine tumour with lateral and suprasellar extension, peripheral ACTH staining and ring like staining in AE1/AE3 stain, the diagnosis of a Crooke cell tumour could be made.
Our case report brings out a unique presentation of a rare Crooke cell tumour developing apoplexy in the background of progressive Cushing disease. Delayed presentation leading to lack of timely intervention might have resulted in this consequence which has never being reported before.

Acknowledgements

Authors would like to acknowledge the patient who gave consent to publish this case report.

Declarations

Not applicable.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

All the authors declare that there is no conflict of interest regarding the publication of this manuscript.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
Metadaten
Titel
Apoplexy of Crooke cell tumour leading to the diagnosis of severe Cushing disease; a case report
verfasst von
Nipun Lakshitha de Silva
Noel Somasundaram
Roshana Constantine
Himashi Kularatna
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
BMC Endocrine Disorders / Ausgabe 1/2021
Elektronische ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00761-2

Weitere Artikel der Ausgabe 1/2021

BMC Endocrine Disorders 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.